Research ArticleArticle
Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value
Laura C. Coates, Alice B. Gottlieb, Joseph F. Merola, Caroline Boone, Annette Szumski and Amit Chhabra
The Journal of Rheumatology October 2018, jrheum.180249; DOI: https://doi.org/10.3899/jrheum.180249
Laura C. Coates
From the Botnar Research Centre, University of Oxford, Oxford, UK; New York Medical College at Metropolitan Hospital, New York, New York, USA; Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Pfizer, Brussels, Belgium; inVentiv Health, Princeton, New Jersey, USA; Pfizer, New York, New York, USA. This study was funded by Pfizer. L.C. Coates is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Medical writing support was provided by Sabrina Giavara, PhD, of Engage Scientific Solutions, and was funded by Pfizer. LCC has received fees from AbbVie, Novartis, and UCB. ABG has received fees from Janssen Inc., AbbVie, UCB, Novartis, and Eli Lilly. JFM is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Eli Lilly and Co., Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. AS is an employee of inVentiv and was contracted by Pfizer in connection with the development of the manuscript. AC is an employee of Pfizer. CB was employed by Pfizer at the time of the study. L.C. Coates, MBChB, PhD, NIHR Clinician Scientist, Botnar Research Centre, University of Oxford; A.B. Gottlieb, MD, PhD, Professor of Dermatology, Department of Dermatology, New York Medical College, Metropolitan Hospital; J.F. Merola, MD, MMSc, Brigham and Women’s Hospital, Harvard Medical School; C. Boone, PharmD, (formerly) Medical Manager, Pfizer Innovative Health, Medical Department, Pfizer, Brussels, at the time of the study; A. Szumski, MS, Principal Statistician, inVentiv Health; A. Chhabra, MBBS, MPH, Senior Medical Director, Pfizer, New York. Address correspondence to L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: laura.coates@ndorms.ox.ac.uk. Accepted for publication June 28, 2018.
Alice B. Gottlieb
From the Botnar Research Centre, University of Oxford, Oxford, UK; New York Medical College at Metropolitan Hospital, New York, New York, USA; Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Pfizer, Brussels, Belgium; inVentiv Health, Princeton, New Jersey, USA; Pfizer, New York, New York, USA. This study was funded by Pfizer. L.C. Coates is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Medical writing support was provided by Sabrina Giavara, PhD, of Engage Scientific Solutions, and was funded by Pfizer. LCC has received fees from AbbVie, Novartis, and UCB. ABG has received fees from Janssen Inc., AbbVie, UCB, Novartis, and Eli Lilly. JFM is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Eli Lilly and Co., Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. AS is an employee of inVentiv and was contracted by Pfizer in connection with the development of the manuscript. AC is an employee of Pfizer. CB was employed by Pfizer at the time of the study. L.C. Coates, MBChB, PhD, NIHR Clinician Scientist, Botnar Research Centre, University of Oxford; A.B. Gottlieb, MD, PhD, Professor of Dermatology, Department of Dermatology, New York Medical College, Metropolitan Hospital; J.F. Merola, MD, MMSc, Brigham and Women’s Hospital, Harvard Medical School; C. Boone, PharmD, (formerly) Medical Manager, Pfizer Innovative Health, Medical Department, Pfizer, Brussels, at the time of the study; A. Szumski, MS, Principal Statistician, inVentiv Health; A. Chhabra, MBBS, MPH, Senior Medical Director, Pfizer, New York. Address correspondence to L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: laura.coates@ndorms.ox.ac.uk. Accepted for publication June 28, 2018.
Joseph F. Merola
From the Botnar Research Centre, University of Oxford, Oxford, UK; New York Medical College at Metropolitan Hospital, New York, New York, USA; Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Pfizer, Brussels, Belgium; inVentiv Health, Princeton, New Jersey, USA; Pfizer, New York, New York, USA. This study was funded by Pfizer. L.C. Coates is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Medical writing support was provided by Sabrina Giavara, PhD, of Engage Scientific Solutions, and was funded by Pfizer. LCC has received fees from AbbVie, Novartis, and UCB. ABG has received fees from Janssen Inc., AbbVie, UCB, Novartis, and Eli Lilly. JFM is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Eli Lilly and Co., Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. AS is an employee of inVentiv and was contracted by Pfizer in connection with the development of the manuscript. AC is an employee of Pfizer. CB was employed by Pfizer at the time of the study. L.C. Coates, MBChB, PhD, NIHR Clinician Scientist, Botnar Research Centre, University of Oxford; A.B. Gottlieb, MD, PhD, Professor of Dermatology, Department of Dermatology, New York Medical College, Metropolitan Hospital; J.F. Merola, MD, MMSc, Brigham and Women’s Hospital, Harvard Medical School; C. Boone, PharmD, (formerly) Medical Manager, Pfizer Innovative Health, Medical Department, Pfizer, Brussels, at the time of the study; A. Szumski, MS, Principal Statistician, inVentiv Health; A. Chhabra, MBBS, MPH, Senior Medical Director, Pfizer, New York. Address correspondence to L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: laura.coates@ndorms.ox.ac.uk. Accepted for publication June 28, 2018.
Caroline Boone
From the Botnar Research Centre, University of Oxford, Oxford, UK; New York Medical College at Metropolitan Hospital, New York, New York, USA; Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Pfizer, Brussels, Belgium; inVentiv Health, Princeton, New Jersey, USA; Pfizer, New York, New York, USA. This study was funded by Pfizer. L.C. Coates is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Medical writing support was provided by Sabrina Giavara, PhD, of Engage Scientific Solutions, and was funded by Pfizer. LCC has received fees from AbbVie, Novartis, and UCB. ABG has received fees from Janssen Inc., AbbVie, UCB, Novartis, and Eli Lilly. JFM is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Eli Lilly and Co., Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. AS is an employee of inVentiv and was contracted by Pfizer in connection with the development of the manuscript. AC is an employee of Pfizer. CB was employed by Pfizer at the time of the study. L.C. Coates, MBChB, PhD, NIHR Clinician Scientist, Botnar Research Centre, University of Oxford; A.B. Gottlieb, MD, PhD, Professor of Dermatology, Department of Dermatology, New York Medical College, Metropolitan Hospital; J.F. Merola, MD, MMSc, Brigham and Women’s Hospital, Harvard Medical School; C. Boone, PharmD, (formerly) Medical Manager, Pfizer Innovative Health, Medical Department, Pfizer, Brussels, at the time of the study; A. Szumski, MS, Principal Statistician, inVentiv Health; A. Chhabra, MBBS, MPH, Senior Medical Director, Pfizer, New York. Address correspondence to L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: laura.coates@ndorms.ox.ac.uk. Accepted for publication June 28, 2018.
Annette Szumski
From the Botnar Research Centre, University of Oxford, Oxford, UK; New York Medical College at Metropolitan Hospital, New York, New York, USA; Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Pfizer, Brussels, Belgium; inVentiv Health, Princeton, New Jersey, USA; Pfizer, New York, New York, USA. This study was funded by Pfizer. L.C. Coates is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Medical writing support was provided by Sabrina Giavara, PhD, of Engage Scientific Solutions, and was funded by Pfizer. LCC has received fees from AbbVie, Novartis, and UCB. ABG has received fees from Janssen Inc., AbbVie, UCB, Novartis, and Eli Lilly. JFM is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Eli Lilly and Co., Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. AS is an employee of inVentiv and was contracted by Pfizer in connection with the development of the manuscript. AC is an employee of Pfizer. CB was employed by Pfizer at the time of the study. L.C. Coates, MBChB, PhD, NIHR Clinician Scientist, Botnar Research Centre, University of Oxford; A.B. Gottlieb, MD, PhD, Professor of Dermatology, Department of Dermatology, New York Medical College, Metropolitan Hospital; J.F. Merola, MD, MMSc, Brigham and Women’s Hospital, Harvard Medical School; C. Boone, PharmD, (formerly) Medical Manager, Pfizer Innovative Health, Medical Department, Pfizer, Brussels, at the time of the study; A. Szumski, MS, Principal Statistician, inVentiv Health; A. Chhabra, MBBS, MPH, Senior Medical Director, Pfizer, New York. Address correspondence to L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: laura.coates@ndorms.ox.ac.uk. Accepted for publication June 28, 2018.
Amit Chhabra
From the Botnar Research Centre, University of Oxford, Oxford, UK; New York Medical College at Metropolitan Hospital, New York, New York, USA; Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; Pfizer, Brussels, Belgium; inVentiv Health, Princeton, New Jersey, USA; Pfizer, New York, New York, USA. This study was funded by Pfizer. L.C. Coates is funded by a UK National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Medical writing support was provided by Sabrina Giavara, PhD, of Engage Scientific Solutions, and was funded by Pfizer. LCC has received fees from AbbVie, Novartis, and UCB. ABG has received fees from Janssen Inc., AbbVie, UCB, Novartis, and Eli Lilly. JFM is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Eli Lilly and Co., Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. AS is an employee of inVentiv and was contracted by Pfizer in connection with the development of the manuscript. AC is an employee of Pfizer. CB was employed by Pfizer at the time of the study. L.C. Coates, MBChB, PhD, NIHR Clinician Scientist, Botnar Research Centre, University of Oxford; A.B. Gottlieb, MD, PhD, Professor of Dermatology, Department of Dermatology, New York Medical College, Metropolitan Hospital; J.F. Merola, MD, MMSc, Brigham and Women’s Hospital, Harvard Medical School; C. Boone, PharmD, (formerly) Medical Manager, Pfizer Innovative Health, Medical Department, Pfizer, Brussels, at the time of the study; A. Szumski, MS, Principal Statistician, inVentiv Health; A. Chhabra, MBBS, MPH, Senior Medical Director, Pfizer, New York. Address correspondence to L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. E-mail: laura.coates@ndorms.ox.ac.uk. Accepted for publication June 28, 2018.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value
Laura C. Coates, Alice B. Gottlieb, Joseph F. Merola, Caroline Boone, Annette Szumski, Amit Chhabra
The Journal of Rheumatology Oct 2018, jrheum.180249; DOI: 10.3899/jrheum.180249
Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value
Laura C. Coates, Alice B. Gottlieb, Joseph F. Merola, Caroline Boone, Annette Szumski, Amit Chhabra
The Journal of Rheumatology Oct 2018, jrheum.180249; DOI: 10.3899/jrheum.180249